Skip to content

Enclomiphene

Enclomiphene is a selective oestrogen receptor modulator developed for secondary hypogonadism in adult men. It is the trans form of clomiphene, an older fertility medicine.

Medicine containing Enclomiphene

Androxal

Secondary Hypogonadism

50mg

The Androxal tablets contain enclomiphene for secondary hypogonadism. It comes in one strength and several pack sizes. Each option lists its price per tablet.

FromUS$0.77/ tabletView

Key points

  • Enclomiphene was developed for secondary hypogonadism in adult men, in which the pituitary fails to prompt the testes to produce sufficient testosterone.
  • Onset is given as 1 to 2 weeks.
  • It is contraindicated in hypersensitivity to enclomiphene, in pregnancy and in breastfeeding, and is for adults only.

What enclomiphene is used for

Secondary hypogonadism means low testosterone that starts with the pituitary rather than the testes. Enclomiphene was studied for this in adult men. It is also used off-label for male infertility, as clomiphene is at times; no approval covers either use. Low testosterone has several causes, so testing comes before any treatment, and anyone with symptoms should see a doctor first.

How it works

Enclomiphene blocks oestrogen receptors, which the brain reads as a signal to release more gonadotropins, supporting the body’s own testosterone production.

Forms and brands

Androxal 50mg tablets contain enclomiphene and are listed for secondary hypogonadism. Pharmacy partners in India ship to Malaysia in discreet packaging.

Safety

Clomiphene, the parent medicine, is contraindicated in liver disease or a history of liver dysfunction. Headache, nausea, hot flushes, acne, dizziness and decreased libido can occur. Thromboembolism and visual disturbance are serious and need immediate medical attention; with clomiphene, blurring, spots or flashes may be prolonged or irreversible at higher doses or longer duration.

What the sources say

  • Enclomiphene is the trans isomer of clomiphene, a mixture of cis (zuclomiphene) and trans (enclomiphene) isomers. (EMA)
  • The EMA’s committee issued a negative opinion and did not grant marketing authorisation for EnCyzix (enclomifene citrate). (EMA)
  • Ovarian hyperstimulation syndrome has been reported with clomiphene citrate therapy and may progress rapidly to a serious medical disorder. (FDA)

Further reading

Last updated